Patients’ baseline characteristics
| Variables | Secukinumab | Placebo N=50 | |||
|---|---|---|---|---|---|
| 25 mg N=54 | 75 mg N=49 | 150 mg N=43 | 300 mg N=41 | ||
| Age (years) | 53.3±11.4 | 54.3±9.8 | 57.8±11.2 | 54.7±10.6 | 55.0±10.5 |
| Women† | 45 (83.3) | 38 (77.6) | 35 (81.4) | 31 (75.6) | 34 (68.0) |
| BMI (kg/m2) | 26.7±4.8 | 27.03±4.9 | 27.43±4.7 | 29.45±8.4 | 27.45±5.2 |
| Duration of RA (years) | 6.7±6.0 | 8.6±7.3 | 7.9±9.2 | 5.9±6.5 | 6.8±6.5 |
| Adjusted swollen 28-joint count* | 11.1±5.2 | 11.0±4.7 | 10.9±4.8 | 11.7±4.7 | 10.7±4.2 |
| Adjusted tender 28-joint count* | 14.6±6.8 | 13.5±6.2 | 14.4±6.1 | 15.3±5.8 | 14.5±6.3 |
| Previous use of biological agents† | 12 (22.2) | 9 (18.4) | 9 (20.9) | 8 (19.5) | 10 (20.0) |
| hsCRP (mg/l)^ | 9.5 (0.3–88.9) | 16.3 (0.3–131.0) | 10.4.2 (0–186.0) | 7.5 (0–186.0) | 11.1 (0.6–120.0) |
| DAS28–CRP | 5.6±0.9 | 5.7±0.9 | 5.7±0.9 | 5.7±0.8 | 5.6±0.7 |
| DAS28–ESR | 6.4±0.8 | 6.5±0.8 | 6.4±0.8 | 6.4±0.8 | 6.3±0.7 |
| HAQ score | 1.4±0.7 | 1.5±0.6 | 1.5±0.6 | 1.6±0.5 | 1.4±0.6 |
| RF positive (≥12 U/ml)† | 40 (74.1) | 39 (79.6) | 29 (67.4) | 31 (75.6) | 37 (74.0) |
| Anti-CCP positive (≥20 U/l)† | 43 (79.6) | 43 (87.8) | 31 (72.1) | 31 (75.6) | 36 (72.0) |
| Previous use of anti-TNF† | 9 (16.7) | 3 (6.1) | 6 (14.0) | 4 (9.8) | 7 (14.0) |
Mean±SD is presented, except for those marked with (^) where median range is presented) and (†) where n (%) is presented.
*If the number of joints for which data were available (eg, T) was less than 28, the number of swollen or tender joints (eg, t) was scaled up proportionately (ie, 28*(t/T)).
BMI, body mass index; CCP, cyclic citrullinated peptide; CRP, C-reactive protein; DAS28, disease activity score in 28 joints; ESR, erythrocyte sedimentation rate; HAQ, health assessment questionnaire; hsCRP, high sensitivity C-reactive protein; RA, rheumatoid arthritis; RF, rheumatoid factor; TNF, tumour necrosis factor.